A. yes

A retrospective review of 481 patients found that secondary review by an expert breast pathologist changed the assessed recurrence risk in 29 % of ductal carcinoma in situ (DCIS) cases and altered treatment recommendations in 43 %, leading the authors to conclude that expert pathology assessment “continues to be necessary in the management of DCIS” [Rakovitch et al., 2004, PMID 15528969].